Advertisement
Singapore markets close in 7 hours 45 minutes
  • Straits Times Index

    3,187.98
    +0.32 (+0.01%)
     
  • Nikkei

    37,304.19
    -775.51 (-2.04%)
     
  • Hang Seng

    16,385.87
    0.00 (0.00%)
     
  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     
  • Bitcoin USD

    62,427.37
    +868.88 (+1.41%)
     
  • CMC Crypto 200

    1,298.72
    +413.19 (+46.00%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,398.30
    +0.30 (+0.01%)
     
  • Crude Oil

    83.85
    +1.12 (+1.35%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     
  • Jakarta Composite Index

    7,166.81
    -7,130.84 (-49.87%)
     
  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Analysts’ Recommendations for AbbVie in December

Analysts’ Recommendations for AbbVie in December

The company saw a rise of 17.53% in its share price from $80.21 on November 1 to $94.27 on November 30. Thereafter, AbbVie saw a 3.95% fall in its share price from November 30 to December 5. On November 30, AbbVie issued a press release announcing agreements that granted Pfizer (PFE) a nonexclusive global license related to Humira’s intellectual property.